Alcobra Ltd. (ADHD) Downgraded to Hold at Stifel Nicolaus
Alcobra Ltd. (NASDAQ:ADHD) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, The Fly reports.
ADHD has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Alcobra from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Oppenheimer Holdings Inc. cut shares of Alcobra from an “outperform” rating to a “market perform” rating in a report on Thursday, September 29th. Cantor Fitzgerald cut shares of Alcobra from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a report on Thursday, September 29th. Roth Capital reiterated a “buy” rating and set a $12.00 price target on shares of Alcobra in a report on Tuesday, June 21st. Finally, WBB Securities cut shares of Alcobra from a “hold” rating to a “sell” rating and cut their price target for the company from $5.00 to $4.00 in a report on Monday, September 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. Alcobra presently has an average rating of “Hold” and a consensus price target of $6.47.
Alcobra (NASDAQ:ADHD) traded down 0.77% on Friday, reaching $2.58. 264,854 shares of the company were exchanged. The firm has a 50-day moving average of $4.41 and a 200 day moving average of $4.46. The firm’s market capitalization is $71.11 million. Alcobra has a 12-month low of $1.95 and a 12-month high of $8.78.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/alcobra-ltd-adhd-downgraded-to-hold-at-stifel-nicolaus.html
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. On average, equities analysts predict that Alcobra will post ($0.94) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of ADHD. Stifel Financial Corp increased its position in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares during the period. Palo Alto Investors LLC increased its position in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the period. VHCP Management LLC increased its position in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the period. VHCP Management II LLC increased its position in shares of Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the period. Finally, Jefferies Group LLC bought a new position in shares of Alcobra during the second quarter worth $533,000. Institutional investors own 73.69% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.